Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<p>Tumor-recruited, tumor-retained, and tumor-experienced Tregs, which egress tumors, adopt an altered phenotype after CAN-2409 + prodrug treatment. The effect of CAN-2409 + prodrug treatment on proliferative status of Treg cells was assessed using Ki67 as a marker coupled with the PD-1 expression. <b>A,</b> Representative flow cytometry plots for total, KG<sup>+</sup>, and KR<sup>+</sup> Treg cells. Quantification of tumor experiencing Treg (KR<sup>+</sup>) for proliferation status (Ki67), <b>B</b>, and immune suppressive functional markers (PD-1, <b>C</b>, <i>N</i> = 4–6. Two-tailed <i>t</i> test, *, <i>P</i> < 0.05; ***, <i>P</i> < 0.001.</p>

Original publication

DOI

10.1158/2767-9764.28427830

Type

Publication Date

17/02/2025